New research paper
Nagy Á et al.: KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer, International Journal of Cancer (2017)
Nagy Á et al.: KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer, International Journal of Cancer (2017)
Menyhárt O et al: Guidelines for the selection of functional assays to evaluate the hallmarks of cancer, BBA Reviews on Cancer (2016)
Sztupinszki Zs et al.: Colon cancer subtypes: concordance, effect on survival and selection of the most representative preclinical models, Scientific Reports (2016)
Lánczky A et al. : miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2,178 breast cancer patients, Breast Cancer Res Treat (2016)
Munkácsy Gy, Sztupinszki Zs et al: Validation of RNAi silencing efficiency using gene array data shows 18.5% failure rate across 429 independent experiments, Molecular Therapy — Nucleic Acids (2016)
Szász AM et al: Cancer heterogeneity determined by functional proteomics. Seminars in Cell & Developmental Biology (2016)
Győrffy B et al: Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes. International Journal of Cancer (2016)
Győrffy B et al: Multigene prognostic tests in breast cancer: past, present, future. Breast Cancer Research (2015)
Copyright 2025. All rights reserved
Designed by Zymphonies